<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; is</title>
	<atom:link href="http://www.tapanray.in/tag/is/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>After Mollycoddling China Cracks Down on Pharma MNCs&#8230;But Why Now?</title>
		<link>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now</link>
		<comments>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/#comments</comments>
		<pubDate>Mon, 22 Jul 2013 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[aeon]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Anathema]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Chen]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[clampdown]]></category>
		<category><![CDATA[contaminated]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[crackdown]]></category>
		<category><![CDATA[Danone]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[enforced]]></category>
		<category><![CDATA[exemplary]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grip]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[hazards]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[land]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[meat]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[mollycoddling]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[powder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[principle]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rat]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[staggering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[violations]]></category>
		<category><![CDATA[Zu]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2948</guid>
		<description><![CDATA[In tandem with exemplary growth in the healthcare sector, China has started confronting with some consequential hazards in form of serious regulatory violations involving, besides many others, hospitals, pharmaceutical pricing and food and drug safety, which reportedly include contaminated milk powder and &#8230; <a href="http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Concept of Orphan Drugs for Orphan Diseases is Orphan in India</title>
		<link>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india</link>
		<comments>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/#comments</comments>
		<pubDate>Mon, 10 Sep 2012 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=36</guid>
		<description><![CDATA[Though the percentage of patients suffering from ‘Rare Diseases’ in India is reportedly higher than the  world average, unfortunately even today such cases get little help from our government. According to experts, diseases manifesting patients representing maximum 6 to 8 &#8230; <a href="http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Replication of ‘Old Paradigm’ of the developed pharmaceutical markets is unlikely to yield results in the evolving new paradigm of India</title>
		<link>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india</link>
		<comments>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/#comments</comments>
		<pubDate>Mon, 03 Sep 2012 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Replication]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unlikely]]></category>
		<category><![CDATA[yield]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=40</guid>
		<description><![CDATA[“Health leaps out of science and draws nourishment from the society around it” - Gunnar Myrdal (Swedish Nobel Laureate Economist) The success concoction of the global pharmaceutical industry for India, by and large, still remains to be sustained attempts in &#8230; <a href="http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The New Drug Policy is languishing in a labyrinth</title>
		<link>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-new-drug-policy-is-languishing-in-a-labyrinth</link>
		<comments>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/#comments</comments>
		<pubDate>Mon, 02 Apr 2012 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DPCO95]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[languishing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM2011]]></category>
		<category><![CDATA[NPPP 2011]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=113</guid>
		<description><![CDATA[Drug Price Control has remained the key feature of all Drug Policies of India, since their inception in early 70’s. Most of these policies continued to remain behind their times consistently, without any exception. That said, the Drug Policy 1994 &#8230; <a href="http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Vaccine Market of India: A rejuvenation is in progress</title>
		<link>http://www.tapanray.in/the-vaccine-market-of-india-a-rejuvenation-is-in-progress/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-vaccine-market-of-india-a-rejuvenation-is-in-progress</link>
		<comments>http://www.tapanray.in/the-vaccine-market-of-india-a-rejuvenation-is-in-progress/#comments</comments>
		<pubDate>Mon, 20 Feb 2012 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[progress. MNC]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rejuvenation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=131</guid>
		<description><![CDATA[Even in couple of decades back, ‘Vaccines Market’ in India did not use to be considered as a focus area by many pharmaceutical companies. Commoditization of this market with low profit margin and unpredictable interest of the government/the doctors towards &#8230; <a href="http://www.tapanray.in/the-vaccine-market-of-india-a-rejuvenation-is-in-progress/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-vaccine-market-of-india-a-rejuvenation-is-in-progress/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Encourage vaccine research and improve its access to demonstrate ‘prevention is better than cure’</title>
		<link>http://www.tapanray.in/encourage-vaccine-research-and-improve-its-access-to-demonstrate-prevention-is-better-than-cure/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=encourage-vaccine-research-and-improve-its-access-to-demonstrate-prevention-is-better-than-cure</link>
		<comments>http://www.tapanray.in/encourage-vaccine-research-and-improve-its-access-to-demonstrate-prevention-is-better-than-cure/#comments</comments>
		<pubDate>Mon, 16 Jan 2012 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[demonstrate]]></category>
		<category><![CDATA[Encourage]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[Preventive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=146</guid>
		<description><![CDATA[Vaccines are one of the most successful and cost-effective public health interventions, which help preventing over 2 million deaths every year. The World Health Organization (WHO) defines vaccines as: “A vaccine is any preparation intended to produce immunity to a &#8230; <a href="http://www.tapanray.in/encourage-vaccine-research-and-improve-its-access-to-demonstrate-prevention-is-better-than-cure/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/encourage-vaccine-research-and-improve-its-access-to-demonstrate-prevention-is-better-than-cure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biologic Drugs: The hunt for the ‘Magic Bullets’ is on</title>
		<link>http://www.tapanray.in/biologic-drugs-the-hunt-for-the-magic-bullets-is-on/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biologic-drugs-the-hunt-for-the-magic-bullets-is-on</link>
		<comments>http://www.tapanray.in/biologic-drugs-the-hunt-for-the-magic-bullets-is-on/#comments</comments>
		<pubDate>Mon, 05 Dec 2011 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[bullets]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[hunt]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=165</guid>
		<description><![CDATA[The global pharmaceutical industry is now navigating its way through very cautiously while negotiating an unprecedented ‘patent cliff’, simultaneously with gradually drying-up R&#38;D pipelines. This unique situation has triggered off several global mega Mergers and Acquisitions (M&#38;A) not only involving &#8230; <a href="http://www.tapanray.in/biologic-drugs-the-hunt-for-the-magic-bullets-is-on/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biologic-drugs-the-hunt-for-the-magic-bullets-is-on/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A National Regulatory Standard is necessary for MRs of the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/a-national-regulatory-standard-is-necessary-for-mrs-of-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-national-regulatory-standard-is-necessary-for-mrs-of-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/a-national-regulatory-standard-is-necessary-for-mrs-of-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 03 Oct 2011 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accreditation]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[necessary]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[representative]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=193</guid>
		<description><![CDATA[Medical Representatives (MR) form the bedrock of business success, especially for the pharmaceutical industry in India. The Job of MRs is tough and high voltage one, laced with moments of elation and sprinkles of frustration, while generating prescription demand for &#8230; <a href="http://www.tapanray.in/a-national-regulatory-standard-is-necessary-for-mrs-of-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-national-regulatory-standard-is-necessary-for-mrs-of-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the undiluted ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/#comments</comments>
		<pubDate>Mon, 21 Feb 2011 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=299</guid>
		<description><![CDATA[Many industry experts after having evaluated the provisions of the original draft proposal for forming a Central Drugs Authority (CDA) in the country, commended and supported this laudable initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
